274,876 results on '"Drug resistance"'
Search Results
2. Adults with perinatally acquired HIV; emerging clinical outcomes and data gaps
- Author
-
Henderson, Merle, Fidler, Sarah, and Foster, Caroline
- Published
- 2024
3. Prevalence of drug-resistant tuberculosis in HIV-positive and diabetic patients in Sinaloa, Mexico: A retrospective cross-sectional study
- Author
-
Perez, Analy Aispuro, Osuna-Martínez, Ulises, Espinoza-Gallardo, Jose Angel, Dorantes-Alvarez, Luis Alfredo, Inzunza-Leyva, Gerardo Kenny, Dorantes-Bernal, Kimberly Estefania, and Quinonez-Bastidas, Geovanna Nallely
- Published
- 2024
4. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
- Author
-
Dayyani, Farshid, Chao, Joseph, Lee, Fa-Chyi, Taylor, Thomas, Neumann, Kristen, and Cho, May
- Subjects
ICI ,TKI ,gastroesophageal cancer ,immune checkpoint inhibitor ,Humans ,Female ,Middle Aged ,Male ,Pyridines ,Aged ,Anilides ,Antibodies ,Monoclonal ,Humanized ,Stomach Neoplasms ,Adult ,Aged ,80 and over ,Immune Checkpoint Inhibitors ,Adenocarcinoma ,Esophageal Neoplasms ,Drug Resistance ,Neoplasm ,Antineoplastic Combined Chemotherapy Protocols ,Young Adult ,Esophagogastric Junction - Abstract
BACKGROUND: Most patients with metastatic gastroesophageal adenocarcinoma (mGEA) progress on immune checkpoint inhibitors (ICIs). Novel approaches to overcome resistance to ICI in mGEA are needed. Cabozantinib is a multi-tyrosine kinase inhibitor thought to enhance the immunomodulatory effects of ICI. This study evaluated the combination of cabozantinib and pembrolizumab in ICI refractory or resistant mGEA. METHODS: Investigator-initiated, single-arm, single institution, and phase II study in patients with mGEA. Patients had progressed on ICI and/or had PD-L1 CPS score ≤10%. Cabozantinib dose was 40 mg p.o. daily on days 1-21 of a 21-day cycle, with pembrolizumab 200 mg i.v. on day 1. The primary endpoint was progression-free survival at 6 months (PFS-6). RESULTS: Twenty-seven patients were enrolled. Median age 58 years (24-87), female (n = 14), ECOG 0/1 = 13/14, GC/GEJ = 16/11, and non-Hispanic White/Hispanic/Asian = 12/8/7. The primary endpoint was met. After a median follow-up of 31.4 months (range 3.3-42.5), PFS-6 was 22.2% (95% CI 9.0-39.0). The median PFS and OS are 2.3 months (95% CI 1.7-4.1) and 5.5 months (3.1-14.0), respectively. The most common mutations were TP53 (78.3%) and CDH1/PIK3CA/CTNNB1 (17.4% each). The most common grade (G) treatment-related adverse events (TRAE) were diarrhea (25.9%), fatigue (18.5%), hypertension, and muscle cramps (14.8% each). G3-4 TRAE were seen in n = 3 patients (hypertension, thromboembolic event, esophageal perforation; each n = 1). No G5 was observed. CONCLUSIONS: The addition of cabozantinib to pembrolizumab shows clinical benefit in ICI-resistant or refractory mGEA with a tolerable safety profile. (ClinicalTrials.gov Identifier: NCT04164979. IRB Approved: UCI 18-124, University of California Irvine IRB#20195426.).
- Published
- 2024
5. Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
- Author
-
Wong, Richard, Choi, Michael, Wang, Huan-You, and Kipps, Thomas
- Subjects
Agammaglobulinaemia Tyrosine Kinase ,Leukemia ,Lymphocytic ,Chronic ,B-Cell ,Humans ,Drug Resistance ,Neoplasm ,Protein Kinase Inhibitors ,Mutation ,Female ,Pyrimidines ,Male ,Aged ,Middle Aged - Abstract
Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to non-covalent and now targeted protein degraders. However, contrary to the presumption that protein degraders may be impervious to mutations in BTK, we now present clinical evidence that a mutation in the kinase domain of BTK, namely A428D, can confer disease resistance to a BTK degrader currently in clinical trials, that is BGB-16673. Modeling of a BTK A428D mutation places a negatively charged aspartic acid in place of the hydrophobic side chain of alanine within the binding pocket of another BTK-degrader in clinical development, namely NX-2127, suggesting that CLL cells with BTK A428D also may be resistant to NX-2127, as they already are known to be with either non-covalent or covalent inhibitors of BTK. Consequently, the two BTK degraders furthest advanced in clinical trials potentially may select for CLL cells with BTK A428D that are resistant to all approved BTKis.
- Published
- 2024
6. Pangenome comparison of Bacteroides fragilis genomospecies unveils genetic diversity and ecological insights
- Author
-
Oles, Renee E, Terrazas, Marvic Carrillo, Loomis, Luke R, Hsu, Chia-Yun, Tribelhorn, Caitlin, Belda-Ferre, Pedro, C., Allison, Bryant, MacKenzie, Young, Jocelyn A, Carrow, Hannah C, Sandborn, William J, Dulai, Parambir S, Sivagnanam, Mamata, Pride, David, Knight, Rob, and Chu, Hiutung
- Subjects
Microbiology ,Biological Sciences ,Biomedical and Clinical Sciences ,Microbiome ,Genetics ,Emerging Infectious Diseases ,Digestive Diseases ,Infectious Diseases ,2.2 Factors relating to the physical environment ,2.1 Biological and endogenous factors ,Infection ,Bacteroides fragilis ,Humans ,Genome ,Bacterial ,Genetic Variation ,Gastrointestinal Microbiome ,Phylogeny ,Bacteroides Infections ,Whole Genome Sequencing ,Drug Resistance ,Bacterial ,pangenome ,commensal bacteria ,genomic diversity ,niche adaptation ,Bacteroides - Abstract
Bacteroides fragilis is a Gram-negative commensal bacterium commonly found in the human colon, which differentiates into two genomospecies termed divisions I and II. Through a comprehensive collection of 694 B. fragilis whole genome sequences, we identify novel features distinguishing these divisions. Our study reveals a distinct geographic distribution with division I strains predominantly found in North America and division II strains in Asia. Additionally, division II strains are more frequently associated with bloodstream infections, suggesting a distinct pathogenic potential. We report differences between the two divisions in gene abundance related to metabolism, virulence, stress response, and colonization strategies. Notably, division II strains harbor more antimicrobial resistance (AMR) genes than division I strains. These findings offer new insights into the functional roles of division I and II strains, indicating specialized niches within the intestine and potential pathogenic roles in extraintestinal sites.ImportanceUnderstanding the distinct functions of microbial species in the gut microbiome is crucial for deciphering their impact on human health. Classifying division II strains as Bacteroides fragilis can lead to erroneous associations, as researchers may mistakenly attribute characteristics observed in division II strains to the more extensively studied division I B. fragilis. Our findings underscore the necessity of recognizing these divisions as separate species with distinct functions. We unveil new findings of differential gene prevalence between division I and II strains in genes associated with intestinal colonization and survival strategies, potentially influencing their role as gut commensals and their pathogenicity in extraintestinal sites. Despite the significant niche overlap and colonization patterns between these groups, our study highlights the complex dynamics that govern strain distribution and behavior, emphasizing the need for a nuanced understanding of these microorganisms.
- Published
- 2024
7. Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer
- Author
-
Chen, Bo, Xu, Pengfei, Yang, Joy C, Nip, Christopher, Wang, Leyi, Shen, Yuqiu, Ning, Shu, Shang, Yufeng, Corey, Eva, Gao, Allen C, Gestwicki, Jason E, Wei, Qiang, Liu, Liangren, and Liu, Chengfei
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Genetics ,Biotechnology ,Prostate Cancer ,Urologic Diseases ,2.1 Biological and endogenous factors ,5.1 Pharmaceuticals ,Humans ,Male ,Animals ,Mice ,Drug Resistance ,Neoplasm ,Cell Line ,Tumor ,Prostatic Neoplasms ,Cell Proliferation ,Gene Expression Regulation ,Neoplastic ,Cell Lineage ,Nerve Tissue Proteins ,Xenograft Model Antitumor Assays ,Cell Plasticity ,Receptors ,Cell Surface ,Prognosis ,Membrane Glycoproteins ,Intracellular Signaling Peptides and Proteins ,Oncology & Carcinogenesis ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Treatment-induced neuroendocrine prostate cancer (t-NEPC) often arises from adenocarcinoma via lineage plasticity in response to androgen receptor signaling inhibitors, such as enzalutamide. However, the specific regulators and targets involved in the transition to NEPC are not well understood. Plexin D1 (PLXND1) is a cellular receptor of the semaphorin (SEMA) family that plays important roles in modulating the cytoskeleton and cell adhesion. Here, we found that PLXND1 was highly expressed and positively correlated with neuroendocrine markers in patients with NEPC. High PLXND1 expression was associated with poorer prognosis in prostate cancer patients. Additionally, PLXND1 was upregulated and negatively regulated by androgen receptor signaling in enzalutamide-resistant cells. Knockdown or knockout of PLXND1 inhibited neural lineage pathways, thereby suppressing NEPC cell proliferation, patient derived xenograft (PDX) tumor organoid viability, and xenograft tumor growth. Mechanistically, the heat shock protein 70 (HSP70) regulated PLXND1 protein stability through degradation, and inhibition of HSP70 decreased PLXND1 expression and NEPC organoid growth. In summary, our findings indicate that PLXND1 could serve as a promising therapeutic target and molecular marker for NEPC.
- Published
- 2024
8. A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors.
- Author
-
Park, Sungjoon, Silva, Erica, Singhal, Akshat, Kelly, Marcus, Licon, Kate, Panagiotou, Isabella, Fogg, Catalina, Fong, Samson, Lee, John, Zhao, Xiaoyu, Bachelder, Robin, Parker, Barbara, Yeung, Kay, and Ideker, Trey
- Subjects
Humans ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,Drug Resistance ,Neoplasm ,Deep Learning ,Animals ,Protein Kinase Inhibitors ,Pyridines ,Female ,Piperazines ,Mice ,Cell Line ,Tumor ,Breast Neoplasms ,Xenograft Model Antitumor Assays - Abstract
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However,
- Published
- 2024
9. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.
- Author
-
Goto, Yusuke, Koshizuka, Keiichi, Ando, Toshinori, Izumi, Hiroki, Wu, Xingyu, Sato, Kuniaki, Ishikawa, Tomohiko, Ford, Kyle, Feng, Xiaodong, Wang, Zhiyong, Arang, Nadia, Allevato, Michael, Kishore, Ayush, Mali, Prashant, and Gutkind, Jorge
- Subjects
Humans ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,CRISPR-Cas Systems ,Squamous Cell Carcinoma of Head and Neck ,Piperazines ,Pyridines ,Mice ,Animals ,Drug Resistance ,Neoplasm ,Head and Neck Neoplasms ,Cell Line ,Tumor ,MTOR Inhibitors ,Protein Kinase Inhibitors ,TOR Serine-Threonine Kinases ,Cyclin E ,Xenograft Model Antitumor Assays ,Synthetic Lethal Mutations ,Oncogene Proteins - Abstract
UNLABELLED: The comprehensive genomic analysis of the head and neck squamous cell carcinoma (HNSCC) oncogenome revealed the frequent loss of p16INK4A (CDKN2A) and amplification of cyclin D1 genes in most human papillomavirus-negative HNSCC lesions. However, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown modest effects in the clinic. The aberrant activation of the PI3K/mTOR pathway is highly prevalent in HNSCC, and recent clinical trials have shown promising clinical efficacy of mTOR inhibitors (mTORi) in the neoadjuvant and adjuvant settings but not in patients with advanced HNSCC. By implementing a kinome-wide CRISPR/Cas9 screen, we identified cell-cycle inhibition as a synthetic lethal target for mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergism in HNSCC-derived cells in vitro and in vivo. Remarkably, we found that an adaptive increase in cyclin E1 (CCNE1) expression upon palbociclib treatment underlies the rapid acquired resistance to this CDK4/6 inhibitor. Mechanistically, mTORi inhibits the formation of eIF4G-CCNE1 mRNA complexes, with the consequent reduction in mRNA translation and CCNE1 protein expression. Our findings suggest that mTORi reverts the adaptive resistance to palbociclib. This provides a multimodal therapeutic option for HNSCC by cotargeting mTOR and CDK4/6, which in turn may halt the emergence of palbociclib resistance. SIGNIFICANCE: A kinome-wide CRISPR/Cas9 screen identified cell-cycle inhibition as a synthetic lethal target of mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergistic effects in HNSCC. Mechanistically, mTORis inhibited palbociclib-induced increase in CCNE1.
- Published
- 2024
10. Human cytomegalovirus (HCMV) genetic diversity, drug resistance testing and prevalence of the resistance mutations: A literature review
- Author
-
Grgic, Ivana and Gorenec, Lana
- Published
- 2024
11. Evaluation of outbreak persistence caused by multidrug-resistant and echinocandin-resistant Candida parapsilosis using multidimensional experimental and epidemiological approaches
- Author
-
Daneshnia, Farnaz, Floyd, Daniel J, Ryan, Adam P, Ghahfarokhy, Pegah Mosharaf, Ebadati, Arefeh, Jusuf, Sebastian, Munoz, Julieta, Jeffries, Nathan Elias, Yvanovich, Emma Elizabeth, Apostolopoulou, Anna, Perry, Austin M, Lass-Flörl, Cornelia, Birinci, Asuman, Hilmioğlu-Polat, Süleyha, Ilkit, Macit, Butler, Geraldine, Nobile, Clarissa J, Arastehfar, Amir, and Mansour, Michael K
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Microbiology ,Clinical Sciences ,Medical Microbiology ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,Antimicrobial Resistance ,Women's Health ,Biodefense ,2.1 Biological and endogenous factors ,2.2 Factors relating to the physical environment ,Infection ,Good Health and Well Being ,Animals ,Mice ,Humans ,Candida parapsilosis ,Antifungal Agents ,Drug Resistance ,Fungal ,Echinocandins ,Disease Outbreaks ,Microbial Sensitivity Tests ,Multidrug resistance ,echinocandin resistance ,mannan ,chitin ,Beta-glucan ,Β-glucan ,Clinical sciences ,Epidemiology - Abstract
Candida parapsilosis is known to cause severe and persistent outbreaks in clinical settings. Patients infected with multidrug-resistant C. parapsilosis (MDR Cp) isolates were identified in a large Turkish hospital from 2017-2020. We subsequently identified three additional patients infected with MDR Cp isolates in 2022 from the same hospital and two echinocandin-resistant (ECR) isolates from a single patient in another hospital. The increasing number of MDR and ECR isolates contradicts the general principle that the severe fitness cost associated with these phenotypes could prevent their dominance in clinical settings. Here, we employed a multidimensional approach to systematically assess the fitness costs of MDR and ECR C. parapsilosis isolates. Whole-genome sequencing revealed a novel MDR genotype infecting two patients in 2022. Despite severe in vitro defects, the levels and tolerances of the biofilms of our ECR and MDR isolates were generally comparable to those of susceptible wild-type isolates. Surprisingly, the MDR and ECR isolates showed major alterations in their cell wall components, and some of the MDR isolates consistently displayed increased tolerance to the fungicidal activities of primary human neutrophils and were more immunoevasive during exposure to primary human macrophages. Our systemic infection mouse model showed that MDR and ECR C. parapsilosis isolates had comparable fungal burden in most organs relative to susceptible isolates. Overall, we observed a notable increase in the genotypic diversity and frequency of MDR isolates and identified MDR and ECR isolates potentially capable of causing persistent outbreaks in the future.
- Published
- 2024
12. Cryptic environmental conjugative plasmid recruits a novel hybrid transposon resulting in a new plasmid with higher dispersion potential.
- Author
-
Muñoz-Gutiérrez, Iván, Cantu, Luis, Shanahan, Jack, Girguis, Miray, de la Cruz, Marlene, and Mota-Bravo, Luis
- Subjects
antibiotic resistance ,criptic plasmid ,transposons ,Plasmids ,DNA Transposable Elements ,Escherichia coli ,Conjugation ,Genetic ,Anti-Bacterial Agents ,Lakes ,Drug Resistance ,Multiple ,Bacterial ,Gene Transfer ,Horizontal ,Drug Resistance ,Bacterial - Abstract
UNLABELLED: Cryptic conjugative plasmids lack antibiotic-resistance genes (ARGs). These plasmids can capture ARGs from the vast pool of the environmental metagenome, but the mechanism to recruit ARGs remains to be elucidated. To investigate the recruitment of ARGs by a cryptic plasmid, we sequenced and conducted mating experiments with Escherichia coli SW4848 (collected from a lake) that has a cryptic IncX (IncX4) plasmid and an IncF (IncFII/IncFIIB) plasmid with five genes that confer resistance to aminoglycosides (strA and strB), sulfonamides (sul2), tetracycline [tet(A)], and trimethoprim (dfrA5). In a conjugation experiment, a novel hybrid Tn21/Tn1721 transposon of 22,570 bp (designated Tn7714) carrying the five ARG mobilized spontaneously from the IncF plasmid to the cryptic IncX plasmid. The IncF plasmid was found to be conjugative when it was electroporated into E. coli DH10B (without the IncX plasmid). Two parallel conjugations with the IncF and the new IncX (carrying the novel Tn7714 transposon) plasmids in two separate E. coli DH10B as donors and E. coli J53 as the recipient revealed that the conjugation rate of the new IncX plasmid (with the novel Tn7714 transposon and five ARGs) is more than two orders of magnitude larger than the IncF plasmid. For the first time, this study shows experimental evidence that cryptic environmental plasmids can capture and transfer transposons with ARGs to other bacteria, creating novel multidrug-resistant conjugative plasmids with higher dispersion potential. IMPORTANCE: Cryptic conjugative plasmids are extrachromosomal DNA molecules without antibiotic-resistance genes (ARGs). Environmental bacteria carrying cryptic plasmids with a high conjugation rate threaten public health because they can capture clinically relevant ARGs and rapidly spread them to pathogenic bacteria. However, the mechanism to recruit ARG by cryptic conjugative plasmids in environmental bacteria has not been observed experimentally. Here, we document the first translocation of a transposon with multiple clinically relevant ARGs to a cryptic environmental conjugative plasmid. The new multidrug-resistant conjugative plasmid has a conjugation rate that is two orders of magnitude higher than the original plasmid that carries the ARG (i.e., the new plasmid from the environment can spread ARG more than two orders of magnitude faster). Our work illustrates the importance of studying the mobilization of ARGs in environmental bacteria. It sheds light on how cryptic conjugative plasmids recruit ARGs, a phenomenon at the root of the antibiotic crisis.
- Published
- 2024
13. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
- Author
-
Zhao, Yaqi, Laird, A, Roberts, Kathryn, Yafawi, Rolla, Kantarjian, Hagop, DeAngelo, Daniel, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, OBrien, Susan, Jabbour, Elias, Cassaday, Ryan, Loyd, Melanie, Olsen, Scott, Neale, Geoffrey, Liu, Xueli, Vandendries, Erik, Advani, Anjali, and Mullighan, Charles
- Subjects
Humans ,Inotuzumab Ozogamicin ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Adult ,Female ,Male ,Middle Aged ,Treatment Outcome ,Aged ,Recurrence ,Antineoplastic Agents ,Immunological ,Young Adult ,Drug Resistance ,Neoplasm ,Adolescent - Abstract
The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterations and the efficacy of InO. Of 326 randomized patients, 91 (InO, n = 43; SC, n = 48) had samples evaluable for genomic analysis. The spectrum of gene fusions and other genomic alterations observed was comparable with prior studies of adult ALL. Responses to InO were observed in all leukemic subtypes, genomic alterations, and risk groups. Significantly higher rates of complete remission (CR)/CR with incomplete count recovery were observed with InO vs SC in patients with BCR::ABL1-like ALL (85.7% [6/7] vs 0% [0/5]; P = .0076), with TP53 alterations (100% [5/5] vs 12.5% [1/8]; P = .0047), and in the high-risk BCR::ABL1- (BCR::ABL1-like, low-hypodiploid, KMT2A-rearranged) group (83.3% [10/12] vs 10.5% [2/19]; P < .0001). This retrospective, exploratory analysis of the INO-VATE trial demonstrated potential for benefit with InO for patients with R/R ALL across leukemic subtypes, including BCR::ABL1-like ALL, and for those bearing diverse genomic alterations. Further confirmation of the efficacy of InO in patients with R/R ALL exhibiting the BCR::ABL1-like subtype or harboring TP53 alterations is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT01564784.
- Published
- 2024
14. Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection
- Author
-
Gohil, Shruti K, Septimus, Edward, Kleinman, Ken, Varma, Neha, Avery, Taliser R, Heim, Lauren, Rahm, Risa, Cooper, William S, Cooper, Mandelin, McLean, Laura E, Nickolay, Naoise G, Weinstein, Robert A, Burgess, L Hayley, Coady, Micaela H, Rosen, Edward, Sljivo, Selsebil, Sands, Kenneth E, Moody, Julia, Vigeant, Justin, Rashid, Syma, Gilbert, Rebecca F, Smith, Kim N, Carver, Brandon, Poland, Russell E, Hickok, Jason, Sturdevant, SG, Calderwood, Michael S, Weiland, Anastasiia, Kubiak, David W, Reddy, Sujan, Neuhauser, Melinda M, Srinivasan, Arjun, Jernigan, John A, Hayden, Mary K, Gowda, Abinav, Eibensteiner, Katyuska, Wolf, Robert, Perlin, Jonathan B, Platt, Richard, and Huang, Susan S
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Urologic Diseases ,Patient Safety ,Women's Health ,Infection ,Adult ,Aged ,Female ,Humans ,Male ,Middle Aged ,Anti-Bacterial Agents ,Antimicrobial Stewardship ,Drug Resistance ,Multiple ,Bacterial ,Hospitals ,Community ,Length of Stay ,Medical Order Entry Systems ,Urinary Tract Infections ,Aged ,80 and over ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceUrinary tract infection (UTI) is the second most common infection leading to hospitalization and is often associated with gram-negative multidrug-resistant organisms (MDROs). Clinicians overuse extended-spectrum antibiotics although most patients are at low risk for MDRO infection. Safe strategies to limit overuse of empiric antibiotics are needed.ObjectiveTo evaluate whether computerized provider order entry (CPOE) prompts providing patient- and pathogen-specific MDRO risk estimates could reduce use of empiric extended-spectrum antibiotics for treatment of UTI.Design, setting, and participantsCluster-randomized trial in 59 US community hospitals comparing the effect of a CPOE stewardship bundle (education, feedback, and real-time and risk-based CPOE prompts; 29 hospitals) vs routine stewardship (n = 30 hospitals) on antibiotic selection during the first 3 hospital days (empiric period) in noncritically ill adults (≥18 years) hospitalized with UTI with an 18-month baseline (April 1, 2017-September 30, 2018) and 15-month intervention period (April 1, 2019-June 30, 2020).InterventionsCPOE prompts recommending empiric standard-spectrum antibiotics in patients ordered to receive extended-spectrum antibiotics who have low estimated absolute risk (
- Published
- 2024
15. Stewardship Prompts to Improve Antibiotic Selection for Pneumonia
- Author
-
Gohil, Shruti K, Septimus, Edward, Kleinman, Ken, Varma, Neha, Avery, Taliser R, Heim, Lauren, Rahm, Risa, Cooper, William S, Cooper, Mandelin, McLean, Laura E, Nickolay, Naoise G, Weinstein, Robert A, Burgess, L Hayley, Coady, Micaela H, Rosen, Edward, Sljivo, Selsebil, Sands, Kenneth E, Moody, Julia, Vigeant, Justin, Rashid, Syma, Gilbert, Rebecca F, Smith, Kim N, Carver, Brandon, Poland, Russell E, Hickok, Jason, Sturdevant, SG, Calderwood, Michael S, Weiland, Anastasiia, Kubiak, David W, Reddy, Sujan, Neuhauser, Melinda M, Srinivasan, Arjun, Jernigan, John A, Hayden, Mary K, Gowda, Abinav, Eibensteiner, Katyuska, Wolf, Robert, Perlin, Jonathan B, Platt, Richard, and Huang, Susan S
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Pneumonia ,Pneumonia & Influenza ,Infectious Diseases ,Patient Safety ,Comparative Effectiveness Research ,Lung ,Clinical Research ,Infection ,Aged ,Female ,Humans ,Male ,Middle Aged ,Anti-Bacterial Agents ,Antimicrobial Stewardship ,Drug Resistance ,Multiple ,Bacterial ,Hospitalization ,Medical Order Entry Systems ,Pneumonia ,Bacterial ,United States ,Aged ,80 and over ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportancePneumonia is the most common infection requiring hospitalization and is a major reason for overuse of extended-spectrum antibiotics. Despite low risk of multidrug-resistant organism (MDRO) infection, clinical uncertainty often drives initial antibiotic selection. Strategies to limit empiric antibiotic overuse for patients with pneumonia are needed.ObjectiveTo evaluate whether computerized provider order entry (CPOE) prompts providing patient- and pathogen-specific MDRO infection risk estimates could reduce empiric extended-spectrum antibiotics for non-critically ill patients admitted with pneumonia.Design, setting, and participantsCluster-randomized trial in 59 US community hospitals comparing the effect of a CPOE stewardship bundle (education, feedback, and real-time MDRO risk-based CPOE prompts; n = 29 hospitals) vs routine stewardship (n = 30 hospitals) on antibiotic selection during the first 3 hospital days (empiric period) in non-critically ill adults (≥18 years) hospitalized with pneumonia. There was an 18-month baseline period from April 1, 2017, to September 30, 2018, and a 15-month intervention period from April 1, 2019, to June 30, 2020.InterventionCPOE prompts recommending standard-spectrum antibiotics in patients ordered to receive extended-spectrum antibiotics during the empiric period who have low estimated absolute risk (
- Published
- 2024
16. WGS of intrauterine E. coli from cows with early postpartum uterine infection reveals a non-uterine specific genotype and virulence factors.
- Author
-
Garzon, Adriana, Basbas, Carl, Schlesener, Cory, Silva-Del-Rio, Noelia, Karle, Betsy, Lima, Fabio, Weimer, Bart, and Pereira, Richard
- Subjects
antibiotic resistance ,cattle ,mutation ,uterine infection ,whole-genome sequencing ,Cattle ,Animals ,Female ,Virulence Factors ,Escherichia coli Infections ,Escherichia coli ,Genotype ,Cattle Diseases ,Postpartum Period ,Cross-Sectional Studies ,Whole Genome Sequencing ,Uterine Diseases ,Genome ,Bacterial ,Uterus ,Anti-Bacterial Agents ,Genome-Wide Association Study ,Drug Resistance ,Bacterial - Abstract
Escherichia coli has been attributed to playing a major role in a cascade of events that affect the prevalence and severity of uterine disease in cattle. The objectives of this project were to (i) define the association between the prevalence of specific antimicrobial resistance and virulence factor genes in E. coli with the clinical status related to uterine infection, (ii) identify the genetic relationship between E. coli isolates from cows with diarrhea, with mastitis, and with and without metritis, and (iii) determine the association between the phenotypic and genotypic antimicrobial resistance identified on the E. coli isolated from postpartum cattle. Bacterial isolates (n = 148) were obtained from a larger cross-sectional study. Cows were categorized into one of three clinical groups before enrollment: metritis, cows with purulent discharge, and control cows. For genomic comparison, public genomes (n = 130) from cows with diarrhea, mastitis, and metritis were included in a genome-wide association study, to evaluate differences between the drug classes or the virulence factor category among clinical groups. A distinct E. coli genotype associated with metritis could not be identified. Instead, a high genetic diversity among the isolates from uterine sources was present. A virulence factor previously associated with metritis (fimH) using PCR was not associated with metritis. There was moderate accuracy for whole-genome sequencing to predict phenotypic resistance, which varied depending on the antimicrobial tested. Findings from this study contradict the traditional pathotype classification and the unique intrauterine E. coli genotype associated with metritis in dairy cows.IMPORTANCEMetritis is a common infectious disease in dairy cattle and the second most common reason for treating a cow with antimicrobials. The pathophysiology of the disease is complex and is not completely understood. Specific endometrial pathogenic Escherichia coli have been reported to be adapted to the endometrium and sometimes lead to uterine disease. Unfortunately, the specific genomic details of the endometrial-adapted isolates have not been investigated using enough genomes to represent the genomic diversity of this organism to identify specific virulence genes that are consistently associated with disease development and severity. Results from this study provide key microbial ecological advances by elucidating and challenging accepted concepts for the role of Intrauterine E. coli in metritis in dairy cattle, especially contradicting the existence of a unique intrauterine E. coli genotype associated with metritis in dairy cows, which was not found in our study.
- Published
- 2024
17. Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam.
- Author
-
Adamson, Paul C, Hieu, Vu N, Nhung, Pham H, Whiley, David M, and Chau, Tran M
- Subjects
Neisseria gonorrhoeae: drug effects ,genetics ,Ceftriaxone: therapeutic use ,pharmacology ,Humans ,Vietnam ,Gonorrhea: drug therapy ,microbiology ,Drug Resistance ,Antimicrobial resistance - Published
- 2024
18. Intraspecific variation in antibiotic resistance potential within E. coli.
- Author
-
Suarez, Stacy and Martiny, Adam
- Subjects
antibiotic resistance ,drug resistance evolution ,drug resistance mechanisms ,functional metagenomics ,intraspecific variation ,Escherichia coli ,Anti-Bacterial Agents ,Drug Resistance ,Bacterial ,Microbial Sensitivity Tests ,Humans ,Genetic Variation ,Escherichia coli Infections ,Metagenomics ,Drug Resistance ,Multiple ,Bacterial - Abstract
Intraspecific genomic diversity brings the potential for an unreported and diverse reservoir of cryptic antibiotic resistance genes in pathogens, as cryptic resistance can occur without major mutations and horizontal transmission. Here, we predicted the differences in the types of antibiotics and genes that induce cryptic and latent resistance between micro-diverse Escherichia coli strains. For example, we hypothesize that known resistance genes will be the culprit of latent resistance within clinical strains. We used a modified functional metagenomics method to induce expression in eight E. coli strains. We found a total of 66 individual genes conferring phenotypic resistance to 11 out of 16 antibiotics. A total of 14 known antibiotic resistance genes comprised 21% of total identified genes, whereas the majority (52 genes) were unclassified cryptic resistance genes. Between the eight strains, 1.2% of core orthologous genes were positive (conferred resistance in at least one strain). Sixty-four percent of positive orthologous genes conferred resistance to only one strain, demonstrating high intraspecific variability of latent resistance genes. Cryptic resistance genes comprised most resistance genes among laboratory and clinical strains as well as natural, semisynthetic, and synthetic antibiotics. Known antibiotic resistance genes primarily conferred resistance to multiple antibiotics from varying origins and within multiple strains. Hence, it is uncommon for E. coli to develop cross-cryptic resistance to antibiotics from multiple origins or within multiple strains. We have uncovered prospective and previously unknown resistance genes as well as antibiotics that have the potential to trigger latent antibiotic resistance in E. coli strains from varying origins.IMPORTANCEIntraspecific genomic diversity may be a driving force in the emergence of adaptive antibiotic resistance. Adaptive antibiotic resistance enables sensitive bacterial cells to acquire temporary antibiotic resistance, creating an optimal window for the development of permanent mutational resistance. In this study, we investigate cryptic resistance, an adaptive resistance mechanism, and unveil novel (cryptic) antibiotic resistance genes that confer resistance when amplified within eight E. coli strains derived from clinical and laboratory origins. We identify the potential of cryptic resistance genes to confer cross-resistance to antibiotics from varying origins and within multiple strains. We discern antibiotic characteristics that promote latent resistance in multiple strains, considering intraspecific diversity. This study may help detect novel resistance genes and functional genes that could become responsible for cryptic resistance among diverse strains and antibiotics, thus also identifying potential novel antibiotic targets and mechanisms.
- Published
- 2024
19. IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
- Author
-
Moyer, Cassandra, Lanier, Amanda, Qian, Jing, Coleman, Darian, Hill, Jamal, Vuligonda, Vidyasagar, Sanders, Martin, Mazumdar, Abhijit, and Brown, Powel
- Subjects
Humans ,Animals ,Breast Neoplasms ,Female ,Receptor ,ErbB-2 ,Mice ,Cell Line ,Tumor ,Xenograft Model Antitumor Assays ,Drug Synergism ,Cellular Senescence ,Cell Proliferation ,Apoptosis ,Trastuzumab ,Drug Resistance ,Neoplasm ,Retinoids - Abstract
PURPOSE: Rexinoids, agonists of nuclear retinoid X receptor (RXR), have been used for the treatment of cancers and are well tolerated in both animals and humans. However, the usefulness of rexinoids in treatment of breast cancer remains unknown. This study examines the efficacy of IRX4204, a highly specific rexinoid, in breast cancer cell lines and preclinical models to identify a biomarker for response and potential mechanism of action. EXPERIMENTAL DESIGN: IRX4204 effects on breast cancer cell growth and viability were determined using cell lines, syngeneic mouse models, and primary patient-derived xenograft (PDX) tumors. In vitro assays of cell cycle, apoptosis, senescence, and lipid metabolism were used to uncover a potential mechanism of action. Standard anti-HER2 therapies were screened in combination with IRX4204 on a panel of breast cancer cell lines to determine drug synergy. RESULTS: IRX4204 significantly inhibits the growth of HER2-positive breast cancer cell lines, including trastuzumab and lapatinib-resistant JIMT-1 and HCC1954. Treatment with IRX4204 reduced tumor growth rate in the MMTV-ErbB2 mouse and HER2-positive PDX model by 49% and 44%, respectively. Mechanistic studies revealed IRX4204 modulates lipid metabolism and induces senescence of HER2-positive cells. In addition, IRX4204 demonstrates additivity and synergy with HER2-targeted mAbs, tyrosine kinase inhibitors, and antibody-drug conjugates. CONCLUSIONS: These findings identify HER2 as a biomarker for IRX4204 treatment response and demonstrate a novel use of RXR agonists to synergize with current anti-HER2 therapies. Furthermore, our results suggest that RXR agonists can be useful for the treatment of anti-HER2 resistant and metastatic HER2-positive breast cancer.
- Published
- 2024
20. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
- Author
-
Levis, Mark, Perl, Alexander, Schiller, Gary, Fathi, Amir, Roboz, Gail, Wang, Eunice, Altman, Jessica, Rajkhowa, Trivikram, Ando, Makoto, Suzuki, Takeaki, Subach, Ruth, Maier, Gary, Madden, Timothy, Johansen, Mary, Cheung, Kin, Kurman, Michael, and Smith, Catherine
- Subjects
Humans ,fms-Like Tyrosine Kinase 3 ,Leukemia ,Myeloid ,Acute ,Middle Aged ,Female ,Male ,Adult ,Aged ,Protein Kinase Inhibitors ,Recurrence ,Mutation ,Treatment Outcome ,Drug Resistance ,Neoplasm ,Aged ,80 and over ,Antineoplastic Agents ,Young Adult - Abstract
FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination therapies. FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling. It is effective against most FLT3 activating mutations, and, unlike other inhibitors, is minimally vulnerable to resistance induced by FLT3 ligand. We conducted a phase 1 dose escalation study of oral FF-10101 in patients with relapsed and/or refractory AML, the majority of whom harbored FLT3-activating mutations and/or had prior exposure to FLT3 inhibitors. Fifty-four participants enrolled in cohorts receiving doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID). The dose limiting toxicities were diarrhea and QT prolongation. Among 40 response-evaluable participants, the composite complete response rate was 10%, and the overall response rate (including partial responses) was 12.5%, including patients who had progressed on gilteritinib. Overall, 56% of participants had prior exposure to FLT3 inhibitors. The recommended phase 2 dose was 75 mg BID. FF-10101 potentially represents a next-generation advance in the management of FLT3-mutated AML. This trial was registered at www.ClinicalTrials.gov as #NCT03194685.
- Published
- 2024
21. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
- Author
-
Goyette, Marie-Anne, Stevens, Laura, DePinho, Carolyn, Seehawer, Marco, Nishida, Jun, Li, Zheqi, Wilde, Callahan, Li, Rong, Qiu, Xintao, Pyke, Alanna, Zhao, Stephanie, Lim, Klothilda, Tender, Gabrielle, Northey, Jason, Riley, Nicholas, Long, Henry, Bertozzi, Carolyn, Polyak, Kornelia, and Weaver, Valerie
- Subjects
HER2 ,brain metastasis ,breast cancer ,resistance ,stroma ,Humans ,Breast Neoplasms ,Female ,Brain Neoplasms ,Drug Resistance ,Neoplasm ,Receptor ,ErbB-2 ,Glycocalyx ,Animals ,Cell Line ,Tumor ,Stromal Cells ,Quinolines ,Mice ,Cell Communication ,Coculture Techniques ,Mucin-1 ,Signal Transduction ,ErbB Receptors - Abstract
Brain metastatic breast cancer is particularly lethal largely due to therapeutic resistance. Almost half of the patients with metastatic HER2-positive breast cancer develop brain metastases, representing a major clinical challenge. We previously described that cancer-associated fibroblasts are an important source of resistance in primary tumors. Here, we report that breast cancer brain metastasis stromal cell interactions in 3D cocultures induce therapeutic resistance to HER2-targeting agents, particularly to the small molecule inhibitor of HER2/EGFR neratinib. We investigated the underlying mechanisms using a synthetic Notch reporter system enabling the sorting of cancer cells that directly interact with stromal cells. We identified mucins and bulky glycoprotein synthesis as top-up-regulated genes and pathways by comparing the gene expression and chromatin profiles of stroma-contact and no-contact cancer cells before and after neratinib treatment. Glycoprotein gene signatures were also enriched in human brain metastases compared to primary tumors. We confirmed increased glycocalyx surrounding cocultures by immunofluorescence and showed that mucinase treatment increased sensitivity to neratinib by enabling a more efficient inhibition of EGFR/HER2 signaling in cancer cells. Overexpression of truncated MUC1 lacking the intracellular domain as a model of increased glycocalyx-induced resistance to neratinib both in cell culture and in experimental brain metastases in immunodeficient mice. Our results highlight the importance of glycoproteins as a resistance mechanism to HER2-targeting therapies in breast cancer brain metastases.
- Published
- 2024
22. Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar.
- Author
-
Delmas, Gilles, Watthanaworawit, Wanitda, McLean, Alistair, Arya, Ann, Reyes, Ann, Li, Xue, Miotto, Olivo, Soe, Kyaw, Ashley, Elizabeth, Dondorp, Arjen, White, Nicholas, Day, Nicholas, Anderson, Tim, Imwong, Mallika, Nosten, Francois, Smithuis, Frank, Thu, Aung, Phyo, Aung, Pateekhum, Chanapat, Rae, Jade, Landier, Jordi, and Parker, Daniel
- Subjects
P. falciparum ,Artemisinin resistance ,Kelch13 ,Malaria elimination ,Mass drug administration ,Artemisinins ,Myanmar ,Malaria ,Falciparum ,Antimalarials ,Drug Resistance ,Plasmodium falciparum ,Humans ,Cross-Sectional Studies ,Female ,Male ,Adolescent ,Adult ,Mass Drug Administration ,Young Adult ,Mutation ,Child ,Child ,Preschool ,Middle Aged ,Quinolines ,Disease Eradication ,Piperazines - Abstract
BACKGROUND: Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during the elimination campaign (2013-2019) was characterized. METHODS: Throughout the six-year campaign Plasmodium falciparum positive blood samples from symptomatic patients and from cross-sectional surveys were genotyped for mutations in kelch-13-a molecular marker of artemisinin resistance. RESULT: The program resulted in near elimination of falciparum malaria. Of 5162 P. falciparum positive blood samples genotyped, 3281 (63.6%) had K13 mutations. The prevalence of K13 mutations was 73.9% in 2013 and 64.4% in 2019. Overall, there was a small but significant decline in the proportion of K13 mutants (p
- Published
- 2024
23. Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
- Author
-
Arzika, Ahmed, Abdou, Amza, Maliki, Ramatou, Beido, Nassirou, Kadri, Boubacar, Harouna, Abdoul, Galo, Abdoul, Alio, Mankara, Lebas, Elodie, Oldenburg, Catherine, OBrien, Kieran, Chen, Cindi, Zhong, Lina, Zhou, Zhaoxia, Yan, Daisy, Hinterwirth, Armin, Doan, Thuy, Porco, Travis, Keenan, Jeremy, and Lietman, Thomas
- Subjects
Humans ,Azithromycin ,Niger ,Child ,Preschool ,Anti-Bacterial Agents ,Infant ,Female ,Drug Resistance ,Bacterial ,Male ,Macrolides ,Mass Drug Administration ,Child Mortality - Abstract
BACKGROUND: Randomized controlled trials found that twice-yearly mass azithromycin administration (MDA) reduces childhood mortality, presumably by reducing infection burden. World Health Organization (WHO) issued conditional guidelines for mass azithromycin administration in high-mortality settings in sub-Saharan Africa given concerns for antibiotic resistance. While prolonged twice-yearly MDA has been shown to increase antibiotic resistance in small randomized controlled trials, the objective of this study was to determine if macrolide and non-macrolide resistance in the gut increases with the duration of azithromycin MDA in a larger setting. METHODS AND FINDINGS: The Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) study was conducted in Niger from December 2014 to June 2020. It was a cluster-randomized trial of azithromycin (A) versus placebo (P) aimed at evaluating childhood mortality. This is a sub-study in the MORDOR trial to track changes in antibiotic resistance after prolonged azithromycin MDA. A total of 594 communities were eligible. Children 1 to 59 months in 163 randomly chosen communities were eligible to receive treatment and included in resistance monitoring. Participants, staff, and investigators were masked to treatment allocation. At the conclusion of MORDOR Phase I, by design, all communities received an additional year of twice-yearly azithromycin treatments (Phase II). Thus, at the conclusion of Phase II, the treatment history (1 letter per 6-month period) for the participating communities was either (PP-PP-AA) or (AA-AA-AA). In Phase III, participating communities were then re-randomized to receive either another 3 rounds of azithromycin or placebo, thus resulting in 4 treatment histories: Group 1 (AA-AA-AA-AA-A, N = 51), Group 2 (PP-PP-AA-AA-A, N = 40), Group 3 (AA-AA-AA-PP-P, N = 27), and Group 4 (PP-PP-AA-PP-P, N = 32). Rectal swabs from each child (N = 5,340) were obtained 6 months after the last treatment. Each child contributed 1 rectal swab and these were pooled at the community level, processed for DNA-seq, and analyzed for genetic resistance determinants. The primary prespecified outcome was macrolide resistance determinants in the gut. Secondary outcomes were resistance to beta-lactams and other antibiotic classes. Communities recently randomized to azithromycin (groups 1 and 2) had significantly more macrolide resistance determinants than those recently randomized to placebo (groups 3 and 4) (fold change 2.18, 95% CI 1.5 to 3.51, Punadj < 0.001). However, there was no significant increase in macrolide resistance in communities treated 4.5 years (group 1) compared to just the most recent 2.5 years (group 2) (fold change 0.80, 95% CI 0.50 to 1.00, Padj = 0.010), or between communities that had been treated for 3 years in the past (group 3) versus just 1 year in the past (group 4) (fold change 1.00, 95% CI 0.78 to 2.35, Padj = 0.52). We also found no significant differences for beta-lactams or other antibiotic classes. The main limitations of our study were the absence of phenotypic characterization of resistance, no complete placebo arm, and no monitoring outside of Niger limiting generalizability. CONCLUSIONS: In this study, we observed that mass azithromycin distribution for childhood mortality among preschool children in Niger increased macrolide resistance determinants in the gut but that resistance may plateau after 2 to 3 years of treatment. Co-selection to other classes needs to be monitored. TRIAL REGISTRATION: NCT02047981 https://classic.clinicaltrials.gov/ct2/show/NCT02047981.
- Published
- 2024
24. State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
- Author
-
Frankhouser, David E, Rockne, Russell C, Uechi, Lisa, Zhao, Dandan, Branciamore, Sergio, O’Meally, Denis, Irizarry, Jihyun, Ghoda, Lucy, Ali, Haris, Trent, Jeffery M, Forman, Stephen, Fu, Yu-Hsuan, Kuo, Ya-Huei, Zhang, Bin, and Marcucci, Guido
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Rare Diseases ,Clinical Research ,Cancer ,Hematology ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Mice ,Animals ,Transcriptome ,Fusion Proteins ,bcr-abl ,Protein Kinase Inhibitors ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Tetracyclines ,Drug Resistance ,Neoplasm ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can induce long-term remission but are also not curative. Thus, CML is an ideal system to test our hypothesis that transcriptome-based state-transition models accurately predict cancer evolution and treatment response. We collected time-sequential blood samples from tetracycline-off (Tet-Off) BCR::ABL-inducible transgenic mice and wild-type controls. From the transcriptome, we constructed a CML state-space and a three-well leukemogenic potential landscape. The potential's stable critical points defined observable disease states. Early states were characterized by anti-CML genes opposing leukemia; late states were characterized by pro-CML genes. Genes with expression patterns shaped similarly to the potential landscape were identified as drivers of disease transition. Re-introduction of tetracycline to silence the BCR::ABL gene returned diseased mice transcriptomes to a near healthy state, without reaching it, suggesting parts of the transition are irreversible. TKI only reverted the transcriptome to an intermediate disease state, without approaching a state of health; disease relapse occurred soon after treatment. Using only the earliest time-point as initial conditions, our state-transition models accurately predicted both disease progression and treatment response, supporting this as a potentially valuable approach to time clinical intervention, before phenotypic changes become detectable.
- Published
- 2024
25. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
- Author
-
Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel, Hochhaus, Andreas, Lipton, Jeffrey, Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, Kantarjian, Hagop, and Shah, Neil Pravin
- Subjects
Humans ,Drug Resistance ,Neoplasm ,Leukemia ,Myeloid ,Chronic-Phase ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Imidazoles ,Pyridazines ,Fusion Proteins ,bcr-abl ,Protein Kinase Inhibitors ,Antineoplastic Agents - Abstract
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial. However, cardiovascular toxicities, including arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated the efficacy and safety of ponatinib using a novel, response-based, dose-reduction strategy in patients with CP-CML whose disease is resistant to ≥2 TKIs or who harbor T315I. To assess the dose-response relationship and the effect on the safety of ponatinib, we examined the outcomes of patients with CP-CML enrolled in PACE and OPTIC who received 45 mg/day of ponatinib. A propensity score analysis was used to evaluate AOEs across both trials. Survival rates and median time to achieve ≤1% BCR::ABL1IS in OPTIC were similar or better than in PACE. The outcomes of patients with T315I mutations were robust in both trials. Patients in OPTIC had a lower exposure-adjusted incidence of AOEs compared with those in PACE. This analysis demonstrates that response-based dosing for ponatinib improves treatment tolerance and mitigates cardiovascular risk.
- Published
- 2024
26. Application of phylodynamics to identify spread of antimicrobial-resistant Escherichia coli between humans and canines in an urban environment
- Author
-
Walas, Nikolina, Müller, Nicola F, Parker, Emily, Henderson, Abigail, Capone, Drew, Brown, Joe, Barker, Troy, and Graham, Jay P
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Antimicrobial Resistance ,Prevention ,Genetics ,Vaccine Related ,Emerging Infectious Diseases ,Biodefense ,2.2 Factors relating to the physical environment ,Aetiology ,Infection ,Animals ,Humans ,Dogs ,Escherichia coli ,Escherichia coli Infections ,Bayes Theorem ,Anti-Bacterial Agents ,Anti-Infective Agents ,Drug Resistance ,Bacterial ,Antimicrobial resistance ,Canines ,ESBL ,Environment ,Genomic epidemiology ,Phylodynamics ,Environmental Sciences - Abstract
The transmission of antimicrobial resistant bacteria in the urban environment is poorly understood. We utilized genomic sequencing and phylogenetics to characterize the transmission dynamics of antimicrobial resistant Escherichia coli (AMR-Ec) cultured from putative canine (caninep) and human feces present on urban sidewalks in San Francisco, California. We isolated a total of fifty-six AMR-Ec isolates from human (n = 20) and caninep (n = 36) fecal samples from the Tenderloin and South of Market (SoMa) neighborhoods of San Francisco. We then analyzed phenotypic and genotypic antimicrobial resistance (AMR) of the isolates, as well as clonal relationships based on cgMLST and single nucleotide polymorphisms (SNPs) of the core genomes. Using Bayesian inference, we reconstructed the transmission dynamics between humans and caninesp from multiple local outbreak clusters using the marginal structured coalescent approximation (MASCOT). Our results provide evidence for multiple sharing events of AMR-Ec between humans and caninesp. In particular, we found one instance of likely transmission from caninesp to humans as well as an additional local outbreak cluster consisting of one caninep and one human sample. Based on this analysis, it appears that non-human feces act as an important reservoir of clinically relevant AMR-Ec within the urban environment for this study population. This work showcases the utility of genomic epidemiology to reconstruct potential pathways by which antimicrobial resistance spreads.
- Published
- 2024
27. Gut Microbiome Diversity and Antimicrobial Resistance After a Single Dose of Oral Azithromycin in Children: A Randomized Placebo-Controlled Trial.
- Author
-
Doan, Thuy, Liu, Zijun, Sié, Ali, Dah, Clarisse, Bountogo, Mamadou, Ouattara, Mamadou, Coulibaly, Boubacar, Kiemde, Dramane, Zonou, Guillaume, Nebie, Eric, Brogdon, Jessica, Lebas, Elodie, Hinterwirth, Armin, Zhong, Lina, Chen, Cindi, Zhou, Zhaoxia, Porco, Travis, Oldenburg, Catherine, Lietman, Thomas, and Arnold, Benjamin
- Subjects
Humans ,Child ,Preschool ,Azithromycin ,Anti-Bacterial Agents ,Gastrointestinal Microbiome ,Macrolides ,Drug Resistance ,Bacterial - Abstract
Mass antibiotic distribution to preschool children resulted in alterations of the gut microbiome months after distribution. This individually randomized, placebo-controlled trial evaluated changes in the gut microbiome and resistome in children aged 8 days to 59 months after one dose of oral azithromycin in Burkina Faso. A total of 450 children were randomized in a 1:1 ratio to either placebo or azithromycin. Rectal samples were collected at baseline, 2 weeks, and 6 months after randomization and subjected to DNA deep sequencing. Gut microbiome diversity and normalized antimicrobial resistance determinants for different antibiotic classes were evaluated. Azithromycin decreased gut bacterial diversity (Shannon P < 0.0001; inverse Simpson P < 0.001) 2 weeks after treatment relative to placebo. Concurrently, the normalized abundance of macrolide resistance genetic determinants was 243-fold higher (95% CI: 76-fold to 776-fold, P < 0.0001). These alterations did not persist at 6 months, suggesting that disruptions were transient. Furthermore, we were unable to detect resistance changes in other antibiotic classes, indicating that co-resistance with a single course of azithromycin when treated at the individual level was unlikely.
- Published
- 2024
28. Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data
- Author
-
Lam, Jonathan Y, Song, Min-Seob, Kim, Gi-Beom, Shimizu, Chisato, Bainto, Emelia, Tremoulet, Adriana H, Nemati, Shamim, and Burns, Jane C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Humans ,Infant ,Biomarkers ,Drug Resistance ,Immunoglobulins ,Intravenous ,Mucocutaneous Lymph Node Syndrome ,Retrospective Studies ,East Asian People ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Pediatrics ,Paediatrics - Abstract
BackgroundAbout 10-20% of Kawasaki disease (KD) patients are resistant to the initial infusion of intravenous immunoglobin (IVIG). The aim of this study was to assess whether IVIG resistance in KD patients could be predicted using standard clinical and laboratory features.MethodsData were from two cohorts: a Korean cohort of 7101 KD patients from 2015 to 2017 and a cohort of 649 KD patients from San Diego enrolled from 1998 to 2021. Features included laboratory values, the worst Z-score from the initial echocardiogram or during hospitalization, and the five clinical KD signs at presentation.ResultsFive machine learning models achieved a maximum median AUC of 0.711 [IQR: 0.706-0.72] in the Korean cohort and 0.696 [IQR: 0.609-0.722] in the San Diego cohort during stratified 10-fold cross-validation using significant laboratory features identified from univariate analysis. Adding the Z-score, KD clinical signs, or both did not considerably improve the median AUC in either cohort.ConclusionsUsing commonly measured clinical laboratory data alone or in conjunction with echocardiographic findings and clinical features is not sufficient to predict IVIG resistance. Further attempts to predict IVIG resistance will need to incorporate additional data such as transcriptomics, proteomics, and genetics to achieve meaningful predictive utility.ImpactWe demonstrated that laboratory, echocardiographic, and clinical findings cannot predict intravenous immunoglobin (IVIG) resistance to a clinically meaningful extent using machine learning in a homogenous Asian or ethnically diverse population of patients with Kawasaki disease (KD). Visualizing these features using uniform manifold approximation and projection (UMAP) is an important step to evaluate predictive utility in a qualitative manner. Further attempts to predict IVIG resistance in KD patients will need to incorporate novel biomarkers or other specialized features such as genetic differences or transcriptomics to be clinically useful.
- Published
- 2024
29. Molecular surveillance of Kelch 13 polymorphisms in Plasmodium falciparum isolates from Kenya and Ethiopia.
- Author
-
Jeang, Brook, Lee, Ming-Chieh, Atieli, Harrysone, Yewhalaw, Delenasaw, Yan, Guiyun, and Zhong, Daibin
- Subjects
Africa ,Artemisinin resistance ,Malaria ,Plasmodium falciparum ,Humans ,Plasmodium falciparum ,Antimalarials ,Kenya ,Ethiopia ,Drug Resistance ,Artemisinins ,Malaria ,Falciparum ,Mutation ,Antiparasitic Agents ,Protozoan Proteins - Abstract
BACKGROUND: Timely molecular surveillance of Plasmodium falciparum kelch 13 (k13) gene mutations is essential for monitoring the emergence and stemming the spread of artemisinin resistance. Widespread artemisinin resistance, as observed in Southeast Asia, would reverse significant gains that have been made against the malaria burden in Africa. The purpose of this study was to assess the prevalence of k13 polymorphisms in western Kenya and Ethiopia at sites representing varying transmission intensities between 2018 and 2022. METHODS: Dried blood spot samples collected through ongoing passive surveillance and malaria epidemiological studies, respectively, were investigated. The k13 gene was genotyped in P. falciparum isolates with high parasitaemia: 775 isolates from four sites in western Kenya (Homa Bay, Kakamega, Kisii, and Kombewa) and 319 isolates from five sites across Ethiopia (Arjo, Awash, Gambella, Dire Dawa, and Semera). DNA sequence variation and neutrality were analysed within each study site where mutant alleles were detected. RESULTS: Sixteen Kelch13 haplotypes were detected in this study. Prevalence of nonsynonymous k13 mutations was low in both western Kenya (25/783, 3.19%) and Ethiopia (5/319, 1.57%) across the study period. Two WHO-validated mutations were detected: A675V in three isolates from Kenya and R622I in four isolates from Ethiopia. Seventeen samples from Kenya carried synonymous mutations (2.17%). No synonymous mutations were detected in Ethiopia. Genetic variation analyses and tests of neutrality further suggest an excess of low frequency polymorphisms in each study site. Fu and Lis F test statistic in Semera was 0.48 (P > 0.05), suggesting potential population selection of R622I, which appeared at a relatively high frequency (3/22, 13.04%). CONCLUSIONS: This study presents an updated report on the low frequency of k13 mutations in western Kenya and Ethiopia. The WHO-validated R622I mutation, which has previously only been reported along the north-west border of Ethiopia, appeared in four isolates collected from eastern Ethiopia. The rapid expansion of R622I across Ethiopia signals the need for enhanced monitoring of the spread of drug-resistant P. falciparum parasites in East Africa. Although ACT remains currently efficacious in the study areas, continued surveillance is necessary to detect early indicators of artemisinin partial resistance.
- Published
- 2024
30. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.
- Subjects
Humans ,Mycobacterium tuberculosis ,Antitubercular Agents ,Microbial Sensitivity Tests ,Tuberculosis ,Drug Resistance ,Multiple ,Bacterial ,Mutation ,Tuberculosis ,Multidrug-Resistant - Abstract
The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis. However, molecular diagnostics to date have focused largely on first-line drugs and predicting susceptibilities in a binary manner (classifying strains as either susceptible or resistant). Here, we used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration (MIC) in 15,211 Mycobacterium tuberculosis clinical isolates from 23 countries across five continents. We identified 492 unique MIC-elevating variants across 13 drugs, as well as 91 mutations likely linked to hypersensitivity. Our results advance genetics-based diagnostics for tuberculosis and serve as a curated training/testing dataset for development of drug resistance prediction algorithms.
- Published
- 2024
31. Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
- Author
-
Vasudevan, Harish, Payne, Emily, Delley, Cyrille, John Liu, S, Mirchia, Kanish, Sale, Matthew, Lastella, Sydney, Nunez, Maria, Lucas, Calixto-Hope, Eaton, Charlotte, Casey-Clyde, Tim, Magill, Stephen, Chen, William, Braunstein, Steve, Perry, Arie, Jacques, Line, Reddy, Alyssa, Pekmezci, Melike, Abate, Adam, Mccormick, Frank, and Raleigh, David
- Subjects
Animals ,Humans ,Mice ,Mitogen-Activated Protein Kinase Kinases ,Neurilemmoma ,Neurofibromatoses ,Neurofibromatosis 1 ,Neurofibromatosis 2 ,Schwann Cells ,Drug Resistance ,Neoplasm - Abstract
Schwann cell tumors are the most common cancers of the peripheral nervous system and can arise in patients with neurofibromatosis type-1 (NF-1) or neurofibromatosis type-2 (NF-2). Functional interactions between NF1 and NF2 and broader mechanisms underlying malignant transformation of the Schwann lineage are unclear. Here we integrate bulk and single-cell genomics, biochemistry, and pharmacology across human samples, cell lines, and mouse allografts to identify cellular de-differentiation mechanisms driving malignant transformation and treatment resistance. We find DNA methylation groups of Schwann cell tumors can be distinguished by differentiation programs that correlate with response to the MEK inhibitor selumetinib. Functional genomic screening in NF1-mutant tumor cells reveals NF2 loss and PAK activation underlie selumetinib resistance, and we find that concurrent MEK and PAK inhibition is effective in vivo. These data support a de-differentiation paradigm underlying malignant transformation and treatment resistance of Schwann cell tumors and elucidate a functional link between NF1 and NF2.
- Published
- 2024
32. Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis.
- Author
-
Mirzaei, Hossein, Eybpoosh, Sana, Mehrabi, Fatemeh, Shojaei, Mohammad, Khezri, Mehrdad, Nasiri, Naser, Sharifi, Hamid, and Mirzazadeh, Ali
- Subjects
Anti-retroviral agents ,Drug resistance ,HIV infections ,Treatment failure ,Viral ,Humans ,Iran ,Reverse Transcriptase Inhibitors ,Prevalence ,HIV-1 ,Drug Resistance ,Viral ,HIV Infections ,Anti-HIV Agents ,Mutation - Abstract
BACKGROUND: There is no systematic review on the prevalence of HIV drug resistance (HIVDR) in Iran. We aimed to estimate the prevalence of HIVDR among people living with HIV (PLHIV) in Iran. We assessed HIVDR prevalence in antiretroviral therapy (ART) naïve PLHIV (i.e., those without a history of ART) and PLHIV receiving ART. METHOD: We systematically searched Scopus, PubMed, Web of Science, Embase, Iranian databases (Iranian Medical Research Information System, Magiran, and Scientific Information Database), the references of studies, and Google Scholar until March 2023. A random-effects model was used to calculate a point estimate and 95% confidence interval (95% CI) for the prevalence of HIVDR in PLHIV. RESULTS: Among 461 potential publications, 22 studies were included in the meta-analysis. The pooled prevalence of acquired HIVDR in PLHIV receiving ART was 34% (95% CI: 19, 50) for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 27% (95% CI: 15, 41) for non-nucleoside reverse transcriptase inhibitors (NNRTIs), and 9% (95% CI: 3, 18) for protease inhibitors (PIs). The pooled prevalence of acquired HIVDR in treatment failure PLHIV was 50% (95% CI: 31, 69) for NRTIs, 49% (95% CI: 29, 69) for NNRTIs, 11% (95% CI: 2, 24) for PIs, and 1% (95% CI: 0, 4) for integrase inhibitors (INIs). The pooled prevalence of transmitted HIVDR in ART-naïve people was 3% (95% CI; 1, 6) for NRTIs, 5% (95% CI: 2, 9) for NNRTIs, and 0 for PIs and INIs. CONCLUSION: The prevalence of HIVDR was relatively high in both ART-naïve PLHIV and those receiving ART. Without universal pretreatment HIVDR testing and more frequent routine HIV viral load testing among PLHIV who are on ART, the HIVDR prevalence might increase in PLHIV in Iran.
- Published
- 2024
33. Genomic Insights of a Methicillin-Resistant Biofilm-Producing Staphylococcus aureus Strain Isolated From Food Handlers.
- Author
-
Ballah, Fatimah, Hoque, M, Islam, Md, Faisal, Golam, Rahman, Al-Muksit, Khatun, Mst, Rahman, Marzia, Hassan, Jayedul, and Rahman, Md
- Subjects
Staphylococcus aureus ,antibiotic resistance ,biofilm production ,food handlers ,hand swab ,virulence ,Biofilms ,Humans ,Methicillin-Resistant Staphylococcus aureus ,Staphylococcal Infections ,Whole Genome Sequencing ,Genomics ,Genome ,Bacterial ,Food Handling ,Anti-Bacterial Agents ,Microbial Sensitivity Tests ,Virulence ,Virulence Factors ,Phylogeny ,Drug Resistance ,Multiple ,Bacterial - Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is an important zoonotic pathogen associated with a wide range of infections in humans and animals. Thus, the emergence of MRSA clones poses an important threat to human and animal health. This study is aimed at elucidating the genomics insights of a strong biofilm-producing and multidrug-resistant (MDR) S. aureus MTR_BAU_H1 strain through whole-genome sequencing (WGS). The S. aureus MTR_BAU_H1 strain was isolated from food handlers hand swabs in Bangladesh and phenotypically assessed for antimicrobial susceptibility and biofilm production assays. The isolate was further undergone to high throughput WGS and analysed using different bioinformatics tools to elucidate the genetic diversity, molecular epidemiology, sequence type (ST), antimicrobial resistance, and virulence gene distribution. Phenotypic analyses revealed that the S. aureus MTR_BAU_H1 strain is a strong biofilm-former and carries both antimicrobial resistance (e.g., methicillin resistance; mecA, beta-lactam resistance; blaZ and tetracycline resistance; tetC) and virulence (e.g., sea, tsst, and PVL) genes. The genome of the S. aureus MTR_BAU_H1 belonged to ST1930 that possessed three plasmid replicons (e.g., rep16, rep7c, and rep19), seven prophages, and two clustered regularly interspaced short palindromic repeat (CRISPR) arrays of varying sizes. Phylogenetic analysis showed a close evolutionary relationship between the MTR_BAU_H1 genome and other MRSA clones of diverse hosts and demographics. The MTR_BAU_H1 genome harbours 42 antimicrobial resistance genes (ARGs), 128 virulence genes, and 273 SEED subsystems coding for the metabolism of amino acids, carbohydrates, proteins, cofactors, vitamins, minerals, and lipids. This is the first-ever WGS-based study of a strong biofilm-producing and MDR S. aureus strain isolated from human hand swabs in Bangladesh that unveils new information on the resistomes (ARGs and correlated mechanisms) and virulence potentials that might be linked to staphylococcal pathogenesis in both humans and animals.
- Published
- 2024
34. In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells
- Author
-
Jado, Juan Carlos, Dow, Michelle, Carolino, Krypton, Klie, Adam, Fonseca, Gregory J, Ideker, Trey, Carter, Hannah, and Winzeler, Elizabeth A
- Subjects
Biological Sciences ,Bioinformatics and Computational Biology ,Biomedical and Clinical Sciences ,Genetics ,Cancer ,Human Genome ,Antimicrobial Resistance ,Infectious Diseases ,Biotechnology ,5.1 Pharmaceuticals ,Humans ,Haploidy ,Drug Resistance ,Neoplasm ,Antineoplastic Agents ,Genome ,Human ,Whole Genome Sequencing ,Cell Line - Abstract
In vitro evolution and whole genome analysis has proven to be a powerful method for studying the mechanism of action of small molecules in many haploid microbes but has generally not been applied to human cell lines in part because their diploid state complicates the identification of variants that confer drug resistance. To determine if haploid human cells could be used in MOA studies, we evolved resistance to five different anticancer drugs (doxorubicin, gemcitabine, etoposide, topotecan, and paclitaxel) using a near-haploid cell line (HAP1) and then analyzed the genomes of the drug resistant clones, developing a bioinformatic pipeline that involved filtering for high frequency alleles predicted to change protein sequence, or alleles which appeared in the same gene for multiple independent selections with the same compound. Applying the filter to sequences from 28 drug resistant clones identified a set of 21 genes which was strongly enriched for known resistance genes or known drug targets (TOP1, TOP2A, DCK, WDR33, SLCO3A1). In addition, some lines carried structural variants that encompassed additional known resistance genes (ABCB1, WWOX and RRM1). Gene expression knockdown and knockout experiments of 10 validation targets showed a high degree of specificity and accuracy in our calls and demonstrates that the same drug resistance mechanisms found in diverse clinical samples can be evolved, discovered and studied in an isogenic background.
- Published
- 2024
35. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli.
- Author
-
Nasrollahian, Sina, Graham, Jay, and Halaji, Mehrdad
- Subjects
ESBL ,Escherichia coli ,UPEC ,antibiotic resistance ,efflux pump ,Humans ,Escherichia coli ,Escherichia coli Infections ,Microbial Sensitivity Tests ,Anti-Bacterial Agents ,beta-Lactamases ,Drug Resistance ,Microbial - Abstract
The dissemination of antibiotic resistance in Escherichia coli poses a significant threat to public health worldwide. This review provides a comprehensive update on the diverse mechanisms employed by E. coli in developing resistance to antibiotics. We primarily focus on pathotypes of E. coli (e.g., uropathogenic E. coli) and investigate the genetic determinants and molecular pathways that confer resistance, shedding light on both well-characterized and recently discovered mechanisms. The most prevalent mechanism continues to be the acquisition of resistance genes through horizontal gene transfer, facilitated by mobile genetic elements such as plasmids and transposons. We discuss the role of extended-spectrum β-lactamases (ESBLs) and carbapenemases in conferring resistance to β-lactam antibiotics, which remain vital in clinical practice. The review covers the key resistant mechanisms, including: 1) Efflux pumps and porin mutations that mediate resistance to a broad spectrum of antibiotics, including fluoroquinolones and aminoglycosides; 2) adaptive strategies employed by E. coli, including biofilm formation, persister cell formation, and the activation of stress response systems, to withstand antibiotic pressure; and 3) the role of regulatory systems in coordinating resistance mechanisms, providing insights into potential targets for therapeutic interventions. Understanding the intricate network of antibiotic resistance mechanisms in E. coli is crucial for the development of effective strategies to combat this growing public health crisis. By clarifying these mechanisms, we aim to pave the way for the design of innovative therapeutic approaches and the implementation of prudent antibiotic stewardship practices to preserve the efficacy of current antibiotics and ensure a sustainable future for healthcare.
- Published
- 2024
36. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
- Author
-
Phan, Tin, Zitzmann, Carolin, Chew, Kara W, Smith, Davey M, Daar, Eric S, Wohl, David A, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Choudhary, Manish C, Deo, Rinki, Li, Jonathan Z, Ribeiro, Ruy M, Ke, Ruian, Perelson, Alan S, and Team, for the ACTIV-2 A5401 Study
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Coronaviruses Therapeutics and Interventions ,Emerging Infectious Diseases ,Coronaviruses ,Infectious Diseases ,Immunization ,Biodefense ,Biotechnology ,5.2 Cellular and gene therapies ,Infection ,Good Health and Well Being ,Humans ,SARS-CoV-2 ,Antibodies ,Monoclonal ,Spike Glycoprotein ,Coronavirus ,COVID-19 ,COVID-19 Drug Treatment ,Antibodies ,Viral ,Drug Resistance ,Viral ,Viral Load ,Antiviral Agents ,Antibodies ,Neutralizing ,ACTIV-2/A5401 Study Team ,Microbiology ,Virology ,Medical microbiology - Abstract
To mitigate the loss of lives during the COVID-19 pandemic, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of the virus and block its ability to enter and infect target cells. Monoclonal antibody therapy can thus accelerate the decline in viral load and lower hospitalization rates among high-risk patients with variants susceptible to mAb therapy. However, viral resistance has been observed, in some cases leading to a transient viral rebound that can be as large as 3-4 orders of magnitude. As mAbs represent a proven treatment choice for SARS-CoV-2 and other viral infections, evaluation of treatment-emergent mAb resistance can help uncover underlying pathobiology of SARS-CoV-2 infection and may also help in the development of the next generation of mAb therapies. Although resistance can be expected, the large rebounds observed are much more difficult to explain. We hypothesize replenishment of target cells is necessary to generate the high transient viral rebound. Thus, we formulated two models with different mechanisms for target cell replenishment (homeostatic proliferation and return from an innate immune response antiviral state) and fit them to data from persons with SARS-CoV-2 treated with a mAb. We showed that both models can explain the emergence of resistant virus associated with high transient viral rebounds. We found that variations in the target cell supply rate and adaptive immunity parameters have a strong impact on the magnitude or observability of the viral rebound associated with the emergence of resistant virus. Both variations in target cell supply rate and adaptive immunity parameters may explain why only some individuals develop observable transient resistant viral rebound. Our study highlights the conditions that can lead to resistance and subsequent viral rebound in mAb treatments during acute infection.
- Published
- 2024
37. Distribution of bacteria and antimicrobial resistance in retail Nile tilapia (Oreochromis spp.) as potential sources of foodborne illness.
- Author
-
Sripradite, Jarukorn, Thaotumpitak, Varangkana, Atwill, Edward, Hinthong, Woranich, and Jeamsripong, Saharuetai
- Subjects
Animals ,Anti-Bacterial Agents ,Cichlids ,Drug Resistance ,Bacterial ,Thailand ,Ampicillin ,Aeromonas hydrophila ,Salmonella ,Foodborne Diseases - Abstract
This study aimed to investigate AMR profiles of Aeromonas hydrophila, Salmonella spp., and Vibrio cholerae isolated from Nile tilapia (Oreochromis spp.) (n = 276) purchased from fresh markets and supermarkets in Bangkok, Thailand. A sample of tilapia was divided into three parts: fish intestine (n = 276), fish meat (n = 276), and liver and kidney (n = 276). The occurrence of A. hydrophila, Salmonella, and V. cholerae was 3.1%, 7.4%, and 8.5%, respectively. A high prevalence of these pathogenic bacteria was observed in fresh market tilapia compared to those from supermarkets (p < 0.05). The predominant Salmonella serovars were Paratyphi B (6.4%), followed by Escanaba (5.7%), and Saintpaul (5.7%). All isolates tested positive for the virulence genes of A. hydrophila (aero and hly), Salmonella (invA), and V. cholerae (hlyA). A. hydrophila (65.4%), Salmonella (31.2%), and V. cholerae (2.9%) showed multidrug resistant isolates. All A. hydrophila isolates (n = 26) exhibited resistant to ampicillin (100.0%) and florfenicol (100.0%), and often carried sul1 (53.8%) and tetA (50.0%). Salmonella isolates were primarily resistant to ampicillin (36.9%), with a high incidence of blaTEM (26.2%) and qnrS (25.5%). For V. cholerae isolates, resistance was observed against ampicillin (48.6%), and they commonly carried qnrS (24.3%) and tetA (22.9%). To identify mutations in the quinolone resistance determining regions (QRDRs), a single C248A point mutation of C248A (Ser-83-Tyr) in the gyrA region was identified in six out of seven isolates of Salmonella isolates. This study highlighted the presence of antimicrobial-resistant pathogenic bacteria in Nile tilapia at a selling point. It is important to rigorously implement strategies for AMR control and prevention.
- Published
- 2024
38. Impact of zinc supplementation on phenotypic antimicrobial resistance of fecal commensal bacteria from pre-weaned dairy calves
- Author
-
Lee, Katie Y, Atwill, Edward R, Li, Xunde, Feldmann, Hillary R, Williams, Deniece R, Weimer, Bart C, and Aly, Sharif S
- Subjects
Microbiology ,Biological Sciences ,Biomedical and Clinical Sciences ,Complementary and Integrative Health ,Clinical Research ,Antimicrobial Resistance ,Nutrition ,Clinical Trials and Supportive Activities ,Infection ,Animals ,Cattle ,Anti-Bacterial Agents ,Zinc ,Escherichia coli ,Drug Resistance ,Bacterial ,Anti-Infective Agents ,Enterococcus ,Diarrhea ,Organic Chemicals ,Dietary Supplements ,Ciprofloxacin - Abstract
The objective of this study was to evaluate the impact of dietary zinc supplementation in pre-weaned dairy calves on the phenotypic antimicrobial resistance (AMR) of fecal commensal bacteria. A repository of fecal specimens from a random sample of calves block-randomized into placebo (n = 39) and zinc sulfate (n = 28) groups collected over a zinc supplementation clinical trial at the onset of calf diarrhea, calf diarrheal cure, and the last day of 14 cumulative days of zinc or placebo treatment were analyzed. Antimicrobial susceptibility testing was conducted for Enterococcus spp. (n = 167) and E. coli (n = 44), with one representative isolate of each commensal bacteria tested per sample. Parametric survival interval regression models were constructed to evaluate the association between zinc treatment and phenotypic AMR, with exponentiated accelerated failure time (AFT) coefficients adapted for MIC instead of time representing the degree of change in AMR (MIC Ratio, MR). Findings from our study indicated that zinc supplementation did not significantly alter the MIC in Enterococcus spp. for 13 drugs: gentamicin, vancomycin, ciprofloxacin, erythromycin, penicillin, nitrofurantoin, linezolid, quinupristin/dalfopristin, tylosin tartrate, streptomycin, daptomycin, chloramphenicol, and tigecycline (MR = 0.96-2.94, p > 0.05). In E. coli, zinc supplementation was not associated with resistance to azithromycin (MR = 0.80, p > 0.05) and ceftriaxone (MR = 0.95, p > 0.05). However, a significant reduction in E. coli MIC values was observed for ciprofloxacin (MR = 0.17, 95% CI 0.03-0.97) and nalidixic acid (MR = 0.28, 95% CI 0.15-0.53) for zinc-treated compared to placebo-treated calves. Alongside predictions of MIC values generated from these 17 AFT models, findings from this study corroborate the influence of age and antimicrobial exposure on phenotypic AMR.
- Published
- 2024
39. The antibiotic resistance reservoir of the lung microbiome expands with age in a population of critically ill patients
- Author
-
Chu, Victoria T, Tsitsiklis, Alexandra, Mick, Eran, Ambroggio, Lilliam, Kalantar, Katrina L, Glascock, Abigail, Osborne, Christina M, Wagner, Brandie D, Matthay, Michael A, DeRisi, Joseph L, Calfee, Carolyn S, Mourani, Peter M, and Langelier, Charles R
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Microbiology ,Clinical Sciences ,Medical Microbiology ,Antimicrobial Resistance ,Infectious Diseases ,Clinical Research ,Emerging Infectious Diseases ,Biodefense ,Genetics ,Lung ,Pediatric ,Microbiome ,2.1 Biological and endogenous factors ,4.1 Discovery and preclinical testing of markers and technologies ,Respiratory ,Infection ,Good Health and Well Being ,Adult ,Child ,Humans ,Critical Illness ,Anti-Bacterial Agents ,Microbiota ,Drug Resistance ,Microbial ,Respiratory Tract Infections - Abstract
Antimicrobial resistant lower respiratory tract infections are an increasing public health threat and an important cause of global mortality. The lung microbiome can influence susceptibility of respiratory tract infections and represents an important reservoir for exchange of antimicrobial resistance genes. Studies of the gut microbiome have found an association between age and increasing antimicrobial resistance gene burden, however, corollary studies in the lung microbiome remain absent. We performed an observational study of children and adults with acute respiratory failure admitted to the intensive care unit. From tracheal aspirate RNA sequencing data, we evaluated age-related differences in detectable antimicrobial resistance gene expression in the lung microbiome. Using a multivariable logistic regression model, we find that detection of antimicrobial resistance gene expression was significantly higher in adults compared with children after adjusting for demographic and clinical characteristics. This association remained significant after additionally adjusting for lung bacterial microbiome characteristics, and when modeling age as a continuous variable. The proportion of adults expressing beta-lactam, aminoglycoside, and tetracycline antimicrobial resistance genes was higher compared to children. Together, these findings shape our understanding of the lung resistome in critically ill patients across the lifespan, which may have implications for clinical management and global public health.
- Published
- 2024
40. Antimicrobial resistance, virulence profile, and genetic analysis of ESBL-producing Escherichia coli isolated from Nile tilapia in fresh markets and supermarkets in Thailand.
- Author
-
Hinthong, Woranich, Thaotumpitak, Varangkana, Sripradite, Jarukorn, Indrawattana, Nitaya, Srisook, Thassanee, Kongngoen, Thida, R Atwill, Edward, and Jeamsripong, Saharuetai
- Subjects
Animals ,Escherichia coli ,Anti-Bacterial Agents ,Escherichia coli Infections ,Virulence ,Cichlids ,Thailand ,Supermarkets ,beta-Lactamases ,Drug Resistance ,Bacterial ,Ampicillin ,Tetracycline - Abstract
This study investigated the prevalence and antimicrobial resistance (AMR) of Escherichia coli (E. coli) in Nile tilapia from fresh markets and supermarkets. A total of samples (n = 828) were collected from Nile tilapia including fish flesh (n = 276), liver and kidney (n = 276), and intestine (n = 276). Overall prevalence of fecal coliforms (61.6%) and E. coli (53.0%) were observed. High prevalence of E. coli was found in the intestine (71.4%), followed by the liver and kidney (45.7%). The highest prevalence of resistance was commonly found against tetracycline (78.5%), ampicillin (72.8%), and sulfamethoxazole (45.6%) with resistance to only tetracycline (15.2%) as the most common antibiogram. The prevalence of multidrug resistance (MDR) (54.4%) and Extended-spectrum beta-lactamases (ESBLs) (5.7%) were examined. The predominant virulence genes (n = 158) were st (14.6%), followed by eaeA (0.6%). The blaTEM (73.4%), tetA (65.2%), and qnrS (57.6%). There is statistical significance between Nile tilapia from fresh markets and supermarkets. Based on logistic regression analysis, ampicillin-resistant E. coli was statistically associated with the phenotypic resistance to tetracycline and trimethoprim, and the presence of blaTEM and tetA (p < 0.05). Further investigation of AMR transference and their mechanisms is needed for AMR control.
- Published
- 2024
41. Backward bifurcation in a mathematical model of tuberculosis with resistance to drug.
- Author
-
Garba, Usman, Azmi, Amirah, and Mohd, Mohd Hafiz
- Subjects
- *
MULTIDRUG resistance , *DRUG resistance , *TUBERCULOSIS , *BACILLUS (Bacteria) , *INFECTIOUS disease transmission - Abstract
This study focuses on the proliferation of tuberculosis, a contagious condition brought on by Bacillus Mycobacterium, with particular emphasis on its effects on drug-resistant individuals. Tuberculosis treatment is typically 6 to 8 months for newly infected individuals and can extend up to 2.5 years for patients with multi-drug resistance. Despite decades of research, the widespread use of a vaccine, and the seeming WHO attempt to support a single worldwide management approach in recent years, Tuberculosis is the second most common infectious killer, behind covid-19. In 2021, an estimated 10.6 million (9.9-11 million) people latently or actively became ill with TB globally. The dynamics of tuberculosis transmission among the human population are examined using a mathematical model, considering two subgroups: primary infectious individuals and drug-resistant populations. The fundamental reproduction number is obtained, and the model's parameters are subjected to sensitivity analysis to pinpoint the main variables affecting the spread of the disease. The findings of this analysis can aid in proposing effective intervention strategies. The study investigates the TB endemic equilibrium point and evaluates the global and local stability associated with the TB disease-free equilibrium point. Firstly, we examined how the transmission rate affected the model's backward bifurcation. According to our findings, the model experiences a backward bifurcation as the transmission rate rises. Complete eradication of the TB disease becomes unattainable within the range of a scaling factor between 2.53 and 1.73. Secondly, we investigated the effect of the recovery rate among individuals who developed drug resistance on the model's backward bifurcation. Our findings reveal that the model displays a reverse bifurcation as the recovery rate increases. When the transmission rate's scaling factor values shift from 0.5 to 1, the bifurcation changes from forward to backward. Stable disease-free equilibrium (DFE) and global stable endemic equilibria coexist. Based on these observations, we conclude that the drug-resistance compartment is a more significant concern than the infected class, highlighting the need for vigilance among health workers and government agencies in monitoring this silent source of tuberculosis transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Cell aggregation capability of clinical isolates from 'Candida auris' and 'Candida haemulonii' species complex
- Author
-
Ramos, Livia S, Parra-Giraldo, Claudia M, Branquinha, Marta H, and Santos, Andre LS
- Published
- 2023
43. The Relationship Between Renal Functions and Multi Drug Resistant Organisms
- Author
-
Omur ILBAN, Principal investigator
- Published
- 2024
44. Nano-drug delivery systems based on biodegradable polymers for the therapy of gynecological malignancies.
- Author
-
Jin, Keer, Zhang, Hanxue, Yang, Yuwei, and Gao, Yan
- Subjects
- *
DRUG resistance , *POLYMERS , *POLYMER clay , *DISEASE relapse , *WOMEN'S health , *DRUG utilization - Abstract
Gynecological malignancies are the main factors that seriously endanger the life and health of women worldwide. Chemotherapy is one of the traditional methods for the treatment of gynecological malignancies. Conventional chemotherapeutic drugs used in medicine have shortcomings, such as poor target tissue-specific distribution, high toxicity, and side effects. They are prone to problems such as tumor recurrence, invasion, metastasis, and drug resistance. The rapid development of nano-drug delivery systems achieves attenuation, potentiation, inhibition of metastasis, and resistance to drug resistance, bringing hope for the treatment of gynecological malignancies. This article briefly summarizes novel nano-drug delivery systems based on biodegradable polymers and their mediated treatment strategy for gynecological tumors to provide a theoretical basis for developing and clinically translating nano-drug delivery systems for gynecological malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Gemcitabine Resistant Triple Negative Breast Tumor Derived Mesoporous Silicon Nanovaccine Overcame Drug Resistance.
- Author
-
Pan, Wen, Wang, Yangyi, Tian, Shaomin, Ma, Xiaopeng, and Min, Yuanzeng
- Abstract
Drug resistance presents a significant challenge in cancer treatment. By far, there is no effective method to solve this issue. Therapeutic cancer vaccine, which uses tumor antigens, e.g. neoantigens, to activate the hosts’ immune system to eliminate tumor cells, may be effective for overcoming tumor resistance. So, it is hypothesized that resistant tumors may have much more abundant tumor mutations in comparison to naive tumors, and the corresponding vaccine may overcome drug resistance. The proteomics data confirmes that cell lysates from resistant tumors to gemcitabine (GEM), a model drug, contain abundant tumor‐associated antigens, tumor‐specific antigens, damage‐associated molecular patterns, and neoantigens, which can activate immune responses. Herein, to enhance antigen presentation, a mesoporous silicon nanovaccine is developed, which is loaded with antigens from GEM treated GEM‐resistant triple‐negative breast cancer 4T1 cells. When mice bearing GEM‐resistant tumors are vaccinated, the nanovaccine displays efficacy against GEM‐resistant tumors. Moreover, when combined with immunotherapy, the efficacy of the developed nanovaccine on GEM‐resistant tumors are further improved by increasing intratumoral T‐cell infiltrations. The work presents a new strategy for overcoming drug resistance using cancer nanovaccine, which broadens clinical application prospects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
- Author
-
Kulkarni, Aishwarya, Mohan, Varshini, Tang, Tracy T, Post, Leonard, Chan, Yih-Chih, Manning, Murray, Thio, Niko, Parker, Benjamin L, Dawson, Mark A, Rosenbluh, Joseph, Vissers, Joseph HA, and Harvey, Kieran F
- Abstract
The Hippo tumor suppressor pathway controls transcription by regulating nuclear abundance of YAP and TAZ, which activate transcription with the TEAD1-TEAD4 DNA-binding proteins. Recently, several small-molecule inhibitors of YAP and TEADs have been reported, with some entering clinical trials for different cancers with Hippo pathway deregulation, most notably, mesothelioma. Using genome-wide CRISPR/Cas9 screens we reveal that mutations in genes from the Hippo, MAPK, and JAK-STAT signaling pathways all modulate the response of mesothelioma cell lines to TEAD palmitoylation inhibitors. By exploring gene expression programs of mutant cells, we find that MAPK pathway hyperactivation confers resistance to TEAD inhibition by reinstating expression of a subset of YAP/TAZ target genes. Consistent with this, combined inhibition of TEAD and the MAPK kinase MEK, synergistically blocks proliferation of multiple mesothelioma and lung cancer cell lines and more potently reduces the growth of patient-derived lung cancer xenografts in vivo. Collectively, we reveal mechanisms by which cells can overcome small-molecule inhibition of TEAD palmitoylation and potential strategies to enhance the anti-tumor activity of emerging Hippo pathway targeted therapies. Synopsis: Genome-wide CRISPR/Cas9 screens identify mechanisms by which mesothelioma cells respond to TEAD palmitoylation inhibitors, which are the first Hippo pathway targeted therapies. MAPK pathway targeted therapies enhance the anti-tumor activity of TEAD inhibitors. Mutating the Hippo, MAPK, and JAK-STAT pathways modulates the cellular response to TEAD inhibitors. MAPK pathway hyperactivation confers resistance to TEAD inhibition by reinstating expression of a subset of YAP/TAZ targets. Combined inhibition of TEAD and MEK synergistically blocks proliferation of mesothelioma and lung cancer cell lines. MEK inhibitors enhance the ability of TEAD inhibitors to suppress the growth of patient-derived lung cancer xenografts. Genome-wide CRISPR/Cas9 screens identify mechanisms by which mesothelioma cells respond to TEAD palmitoylation inhibitors, which are the first Hippo pathway targeted therapies. MAPK pathway targeted therapies enhance the anti-tumor activity of TEAD inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Patient‐derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.
- Author
-
Bischof, Katharina, Cremaschi, Andrea, Eroukhmanoff, Lena, Landskron, Johannes, Flage‐Larsen, Lise‐Lotte, Gade, Alexandra, Bjørge, Line, Urbanucci, Alfonso, and Taskén, Kjetil
- Subjects
- *
OVARIAN epithelial cancer , *CELLULAR signal transduction , *DRUG resistance , *PROTEIN kinases , *CELL lines - Abstract
Malignant ascites is commonly produced in advanced epithelial ovarian cancer (EOC) and serves as unique microenvironment for tumour cells. Acellular ascites fluid (AAF) is rich in signalling molecules and has been proposed to play a role in the induction of chemoresistance. Through in vitro testing of drug sensitivity and by assessing intracellular phosphorylation status in response to mono‐ and combination treatment of five EOC cell lines after incubation with AAFs derived from 20 different patients, we investigated the chemoresistance‐inducing potential of ascites. We show that the addition of AAFs to the culture media of EOC cell lines has the potential to induce resistance to standard‐of‐care drugs (SCDs). We also show that AAFs induce time‐ and concentration‐dependent activation of downstream signalling to signal transducer and activator of transcription 3 (STAT3), and concomitantly altered phosphorylation of mitogen‐activated protein kinase kinase (MEK), phosphoinositide 3‐kinase (PI3K)–protein kinase B (AKT) and nuclear factor NF‐kappa‐B (NFκB). Antibodies targeting the interleukin‐6 receptor (IL6R) effectively blocked phosphorylation of STAT3 and STAT1. Treatments with SCDs were effective in reducing cell viability in only a third of 30 clinically relevant conditions examined, defined as combinations of drugs, different cell lines and AAFs. Combinations of SCDs and novel therapeutics such as trametinib, fludarabine or rapamycin were superior in another third. Notably, we could nominate effective treatment combinations in almost all conditions except in 4 out of 30 conditions, in which trametinib or fludarabine showed higher efficacy alone. Taken together, our study underscores the importance of the molecular characterisation of individual patients' AAFs and the impact on treatment resistance as providing clinically meaningful information for future precision treatment approaches in EOC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Acetylcytidine modification of DDX41 and ZNF746 by Nacetyltransferase 10 contributes to chemoresistance of melanoma.
- Author
-
Li Wang, Yuefen Zeng, Ying Zhang, Yun Zhu, Shuangyan Xu, and Zuohui Liang
- Abstract
Background: Rapidly developed chemoresistance to dacarbazine (DTIC) is a major obstacle in the clinical management of melanoma; however, the roles and mechanisms of epi-transcriptomic RNA modification in this process have not been investigated. Method: DTIC-resistant (DR) melanoma cells were established for bulk RNA sequencing. The expressions of mRNAs were detected using qRT-PCR, and protein levelswere determined usingWestern blotting and immunohistochemistry. Acetylated RNAs were detected by dot blotting and immunoprecipitation sequencing (acRIPseq). A lung metastasis mouse model of melanoma was established to evaluate the anti-melanoma effects in vivo. Results: We identified that the expression of N-acetyltransferase 10 (NAT10), a catalytic enzyme for the N
4 -acetylcytidine (ac4C) modification of RNA, was significantly upregulated in the DR cells. Clinically, NAT10 expression was elevated in disease progression samples and predicted a poor outcome. Using ac4C RNA immunoprecipitation (ac4C-RIP), we found that the mRNAs of two C2H2 zinc finger transcriptional factors, DDX41 and ZNF746, were targets of NAT10-mediated ac4C modification. Gain- and loss-of-function experiments in NAT10, or in DDX41 and ZNF746, altered the chemosensitivity of melanoma accordingly, and the two target genes also negatively correlated with clinical outcomes. Finally, pharmacological inhibition of NAT10 with Remodelin sensitized melanoma cells to DTIC treatment in vitro and in a mouse xenograft model. Conclusion: Our study elucidates the previously unrecognized role of NAT10-mediated ac4C modification in the chemoresistance of melanoma and provides a rationale for developing new strategies to overcome chemoresistance in melanoma patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
49. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation.
- Author
-
Li, Pengyun, Hu, Xiaotong, Fan, Zhiya, Sun, Shiyang, Ran, Qijie, Wei, Ting, Wei, Pengli, Jiang, Qiyu, Yan, Jian, Yang, Ning, Jia, Changkai, Yang, Tingting, Mao, Yaqiu, Cai, Xu, Xu, Tingting, Zhao, Zhiyuan, Qian, Xiaohong, Qin, Weijie, Zhuang, Xiaomei, and Fan, Feng
- Subjects
- *
DRUG resistance in cancer cells , *DRUG design , *CANCER cell growth , *HEMATOLOGIC malignancies , *ORAL drug administration - Abstract
Background: Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodulatory imide drugs (IMiDs) therapy. Nevertheless, the persistence of inevitable drug resistance and hematological toxicities represents a significant obstacle to their clinical effectiveness. Methods: Phenotypic profiling of a small molecule compounds library in multiple hematological cancer cell lines was conducted to screen for hit degraders. Molecular dynamic-based rational design and cell-based functional assays were conducted to develop more potent degraders. Multiple myeloma (MM) tumor xenograft models were employed to investigate the antitumor efficacy of the degraders as single or combined agents with standard of care agents. Unbiased proteomics was employed to identify multiple therapeutically relevant neosubstrates targeted by the degraders. MM patient-derived cell lines (PDCs) and a panel of solid cancer cell lines were utilized to investigate the effects of candidate degrader on different stage of MM cells and solid malignancies. Unbiased proteomics of IMiDs-resistant MM cells, cell-based functional assays and RT-PCR analysis of clinical MM specimens were utilized to explore the role of BRD9 associated with IMiDs resistance and MM progression. Results: We identified a novel cereblon (CRBN)-dependent lead degrader with phthalazinone scaffold, MGD-4, which induced the degradation of Ikaros proteins. We further developed a novel potent candidate, MGD-28, significantly inhibited the growth of hematological cancer cells and induced the degradation of IKZF1/2/3 and CK1α with nanomolar potency via a Cullin-CRBN dependent pathway. Oral administration of MGD-4 and MGD-28 effectively inhibited MM tumor growth and exhibited significant synergistic effects with standard of care agents. MGD-28 exhibited preferentially profound cytotoxicity towards MM PDCs at different disease stages and broad antiproliferative activity in multiple solid malignancies. BRD9 modulated IMiDs resistance, and the expression of BRD9 was significant positively correlated with IKZF1/2/3 and CK1α in MM specimens at different stages. We also observed pronounced synergetic efficacy between the BRD9 inhibitor and MGD-28 for MM treatment. Conclusions: Our findings present a strategy for the multi-targeted degradation of Ikaros proteins and CK1α against hematological cancers, which may be expanded to additional targets and indications. This strategy may enhance efficacy treatment against multiple hematological cancers and solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Antimalarial drug sulfadoxine induces gametocytogenesis in Plasmodium berghei.
- Author
-
Azmi, Wihda Aisarul, Rizki, Andita Fitri Mutiara, Shidiq, Achmad, Djuardi, Yenny, Artika, I Made, and Siregar, Josephine Elizabeth
- Subjects
- *
PLASMODIUM berghei , *MOLECULAR biology , *PLASMODIUM , *GENE targeting , *DRUG resistance - Abstract
Background: The spread of antimalarial drug resistance parasites is a major obstacle in eliminating malaria in endemic areas. This increases the urgency for developing novel antimalarial drugs with improved profiles to eliminate both sensitive and resistant parasites in populations. The invention of the drug candidates needs a model for sensitive and resistant parasites on a laboratory scale. Methods: Repeated Incomplete Treatment (RIcT) method was followed in raising the rodent malaria parasite, Plasmodium berghei, resistant to sulfadoxine. Plasmodium berghei were exposed to an adequate therapeutic dose of sulfadoxine without finishing the treatment to let the parasite recover. Cycles of drug treatment and parasite recovery were repeated until phenotypic resistance appeared. Results: After undergoing 3–4 cycles, phenotypic resistance was not yet found in mice treated with sulfadoxine. Nevertheless, the molecular biology of dhps gene (the target of sulfadoxine) was analyzed at the end of the RIcT cycle. There was no mutations found in the gene target. Interestingly, the appearance of gametocytes at the end of every cycle of drug treatment and parasite recovery was observed. These gametocytes later on would no longer extend their life in the RBC stage, unless mosquitoes bite the infected host. This phenomenon is similar to the case in human malaria infections treated with sulfadoxine-pyrimethamine (SP). Conclusions: In this study, the antimalarial drug sulfadoxine induced gametocytogenesis in P. berghei, which could raise the risk factor for malaria transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.